Last reviewed · How we verify
Dexchlorpheniramine or Diphenhydramine
Blocks histamine H1 receptors to reduce allergic and inflammatory responses.
Blocks histamine H1 receptors to reduce allergic and inflammatory responses. Used for Allergic rhinitis, Urticaria and pruritus, Allergic reactions.
At a glance
| Generic name | Dexchlorpheniramine or Diphenhydramine |
|---|---|
| Sponsor | Sanofi |
| Drug class | H1 receptor antagonist (first-generation antihistamine) |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Both dexchlorpheniramine and diphenhydramine are first-generation antihistamines that competitively antagonize H1 histamine receptors on target tissues. This prevents histamine-mediated effects such as itching, urticaria, angioedema, and other allergic symptoms. These agents also cross the blood-brain barrier, producing sedation as a common side effect.
Approved indications
- Allergic rhinitis
- Urticaria and pruritus
- Allergic reactions
- Motion sickness (diphenhydramine)
- Sleep aid (diphenhydramine)
Common side effects
- Drowsiness/sedation
- Dry mouth
- Dizziness
- Headache
- Anticholinergic effects (urinary retention, constipation)
Key clinical trials
- Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) (PHASE2)
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexchlorpheniramine or Diphenhydramine CI brief — competitive landscape report
- Dexchlorpheniramine or Diphenhydramine updates RSS · CI watch RSS
- Sanofi portfolio CI